Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
285
resultados
Última actualización
17/01/2026 [06:52:00]
Resultados 175 a 200 de 285
Resumen de: GB2642389A
This disclosure provides the use of nanoparticles of self-assembled acidic molecular clusters (NP-AMCs) of ammonium salts to lower the pH of skin and underlying tissue of a human or other mammal as a means of stimulating the localized immune response to a wound.
Resumen de: MX2025009920A
The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.
Resumen de: MX2025014185A
Provided is a polymer comprising a structure of Formula (1): (1) and a method of preparing said polymer. Also provided is a composition comprising the polymer and a nucleic acid and/or polypeptide, and a method of delivering a nucleic acid and/or polypeptide to a cell.
Resumen de: MX2025014047A
This application disclose a polynucleic acid molecule conjugate comprising an antibody or binding fragment thereof conjugated to a polynucleic acid molecule that hybridizes to a target sequence of an atrogene; wherein the polynucleic acid molecule comprises at least one 2' modified nucleotide, at least one modified intemucleotide linkage, or at least one inverted abasic moiety; and wherein the polynucleic acid molecule conjugate mediates RNA interference against the atrogene, thereby treating muscle atrophy or myotonic dystrophy in a subject. In a certain embodiment, atrogene comprises atrogin-1 gene (FBXO32), MuRF1 gene (TRIA63), FOXO1, FOXO3, or MSTN.
Resumen de: MX2025013817A
The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC), compositions comprising the particles and use thereof for the treatment of PBC.
Resumen de: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Resumen de: MX2025010922A
Provided is an anti-Claudin18.2 nanobody or a binding fragment thereof. The antibody has good specificity, and immune effector cells targeting Claudin18.2 which are prepared from the antibody show a good therapeutic effect in treating or ameliorating diseases having positive expression of Claudin18.2.
Resumen de: MX2025012226A
Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.
Resumen de: MX2025014784A
An engineered RNA molecule, a DNA molecule encoding same and the use thereof. The engineered RNA molecule comprises a poly-A tail sequence containing an MRNA binding site. The poly-A tail can be used to achieve accurate expression of the target gene in organs, tissues and/or cells.
Resumen de: MX2025014295A
The present invention addresses the problem of providing a technology for improving poor water solubility of a compound of general formula (1), and suppressing excessive release of cytokines and myelotoxicity of the compound of general formula (1). The present invention solves the problem by a complex comprising: a modified polysaccharide containing a hydrophobic group; and a compound represented by general formula (1).
Resumen de: EP4674412A1
The present invention relates to a microfluidic device for preparing lipid nanoparticles capable of delivering nucleic acids, and a method for preparing lipid nanoparticles using the same. Using the microfluidic device, lipid nanoparticles having a desired size can be prepared by adjusting the molar ratio of compositions and the Reynolds number.
Resumen de: CN120813339A
There is provided a compound represented by general formula (1) or an ionized form thereof for use in the preparation of lipid nanoparticles encapsulating therapeutic, prophylactic and/or biological agents: wherein NR1R2 is a group ionizable at pH from 3 to physiological pH; a comprises a linear aliphatic hydrocarbon, a branched aliphatic hydrocarbon and/or a cyclic hydrocarbon, optionally comprising one or more groups selected from the group consisting of-OH,-NR-,-O-,-O-CxH2x-O-, where x > = 1; and wherein R is H, an optionally substituted alkyl group, an optionally substituted alkenyl group, or an optionally substituted alkynyl group; r3, R4, R5, R6 and R7 are each independently H, an optionally substituted alkyl group, an optionally substituted alkenyl group or an optionally substituted alkynyl group; and R8 and R9 are each independently a hydrophobic group.
Resumen de: EP4674431A1
The present disclosure is a lipid nanoparticle including a composition including a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, in which the polymer and the protein have opposite charges at a predetermined pH. The lipid nanoparticle preferably has a protein encapsulated therein. In addition, when the particle diameter of the lipid nanoparticles is measured, the peak top of the particle diameter distribution is preferably at 80 nm to 120 nm.
Resumen de: AU2024229078A1
The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.
Resumen de: EP4674856A2
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Resumen de: EP4675006A2
A method of preparing a pharmaceutical composition is provided. The method includes the deposition of a metal oxide layer(s) followed byapplying a polymer layer(s). This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials and one more polymer materials.
Resumen de: EP4674857A2
The present disclosure relates to spheroidal organosiloxane submicron/nanoparticle comprising a network consisting of organosiloxane, and a process to make them.
Resumen de: WO2024130086A1
Disclosed herein are lipid compounds and compositions comprising lipid compounds and methods of making and use thereof. The present disclosure also relates to methods for delivering an agent into a cell by introducing to the cell a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein. Also disclosed herein are methods for promoting wound repair in a subject by administering to the subject a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein.
Resumen de: CN121265555A
本发明属于硒纳米颗粒复合材料技术领域，具体涉及一种巴利森苷修饰的硒纳米颗粒及其制备方法和应用。本发明提供的巴利森苷修饰的硒纳米颗粒，具有核壳结构，包括硒纳米颗粒和包覆在硒纳米颗粒表面的巴利森苷。所述巴利森苷修饰的硒纳米颗粒中巴利森苷分子对葡萄糖转运蛋白‑1具有亲和力，表现出良好的靶向潜力，并具有良好的抗氧化效果。超小剂量的巴利森苷修饰的硒纳米颗粒可通过抗氧化活性缓解过氧化氢造成的不同程度细胞损伤，表现出良好的肝保护效果，可作为一种高效保肝护肝体系。
Resumen de: CN121265554A
本发明属于肿瘤免疫治疗技术领域，具体涉及一种响应型自组装前药纳米粒子及其制备方法和应用，包括喜树碱衍生物CPT‑C、GSH响应型NO前药SIN‑C，联合mPEG2000‑DSPE构建自组装前药纳米粒子SIN/CPT@NPs，制备方法包括将mPEG2000‑DSPE及前药CPT‑C、SIN‑C溶于氯仿，在旋转蒸发仪中形成均匀脂质薄膜，随后加入超纯水进行水化，超声处理获得纳米混悬液，通过离心分离去除未包封药物及大颗粒，收集上清液即得SIN/CPT@NPs，本发明通过肿瘤微环境GSH特异性触发药物释放，同步诱导DNA损伤、STING通路激活及ICD效应，驱动DC成熟与CD8+T细胞浸润，形成化疗‑免疫协同抗肿瘤闭环。
Resumen de: CN121265552A
本发明属于医药技术领域，公开一种负载银纳米粒的脂质体纳米制剂及其制备和应用。本发明采用薄膜分散法制得包载银纳米粒的纳米颗粒。本发明的仿生纳米药物有助于解决抗菌药物银纳米粒细菌摄取效率低的问题，提高药物杀灭瘤内菌的能力，进而提高抗肿瘤效果。制备工艺简单、成本低、稳定性好、可重复性高。
Resumen de: AU2024255212A1
A nanoparticle is described, which comprises a plurality of therapeutic molecules arranged in the form of a spherical micelle, suitable for the localized delivery and release of mycophenolic acid, and therefore effective in the treatment of autoimmune diseases, fibrotic diseases and/or organ rejection diseases, in particular of the lungs. A pharmaceutical composition comprising the nanoparticle in a pharmaceutically acceptable vehicle, and a method for manufacturing said nanoparticle are also described.
Resumen de: CN121265813A
本发明属于生物医药技术领域，具体涉及一种pH响应性纳米药物递送系统及其制备方法与应用。所述pH响应性纳米药物递送系统由羧基化修饰的介孔硅基纳米载体、羧基活化剂和壳聚糖制得；该药物递送系统的制备方法包括提供介孔硅基载体、进行羧基化修饰和壳聚糖接枝三个步骤。本发明通过壳聚糖层实现对肿瘤酸性微环境的响应、以及靶向释放药物，可提高药物的疗效并降低毒副作用，该药物递送系统制备工艺简单、成本低廉、生物相容性好且载药量高。
Resumen de: CN121270966A
本发明公开了一种用于mRNA递送的二硒键交联聚乙烯亚胺载体及其制备方法和用途，所述载体的制备是以合成的二硒‑1,6‑己二醇二丙烯酸酯单体(DSeDA)作为二硒交联剂，与分子量为0.6kDa/1.8kDa的分支PEI通过胺‑丙烯酸酯的Michael加成反应制备二硒交联的聚合物材料，且对未交联的伯胺进行疏水/亲水链的修饰，所述亲/疏水链为化合物CH2COO‑R，取代基R为C8‑C12直链烷基或聚乙二醇的6‑12寡聚体中的一种或几种。本发明载体结构中，交联剂引入可生物降解的二丙烯酸酯键和二硒键，在保持转染效率的同时最大限度地降低毒性。由于二硒键可同时对氧化和还原环境作出灵敏的响应，含二硒键聚合物分子可以成为一类新型的mRNA载体材料，在提高胞内mRNA释放和翻译方面可发挥促进作用。
Nº publicación: CN121271804A 06/01/2026
Solicitante:
中国药科大学
Resumen de: CN121271804A
本发明涉及一种条件激活型免疫细胞及其组合物和应用。具体地，本发明提供一种偶联纳米颗粒的免疫细胞，免疫细胞表达嵌合抗原受体，所述免疫细胞通过连接子与纳米颗粒偶联，其中，所述连接子包含第一肽段，所述第一肽段包含一个或多个配体诱导型蛋白酶水解裂解位点。本发明提供一种定点“开关型”表达嵌合抗原受体的免疫细胞，能够实现对免疫细胞的精准调控，可有效降低靶向脱瘤毒性，进而降低毒副作用，极大地提高了安全性。
BOPI
Sede Electrónica
